Comparative Pharmacology
Head-to-head clinical analysis: CAVERJECT versus CERVIDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAVERJECT versus CERVIDIL.
CAVERJECT vs CERVIDIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Causes relaxation of corpus cavernosum smooth muscle and vasodilation via increased intracellular cyclic guanosine monophosphate (cGMP) due to inhibition of phosphodiesterase type 5 (PDE5) by its active metabolite, alprostadil.
Prostaglandin E2 (PGE2) receptor agonist; induces cervical ripening and uterine contractions via binding to EP receptors, increasing intracellular calcium and promoting gap junction formation.
Initial dose 2.5 micrograms intracavernous injection, titrate to effect; maximum 60 micrograms per injection. Frequency no more than 3 times per week with at least 24 hours between doses.
10 mg vaginal insert (dinoprostone) placed high in the posterior vaginal fornix; may be removed after 12 hours or onset of active labor; one insert per 24 hours.
None Documented
None Documented
Terminal elimination half-life is 1-2 hours; clinically, plasma levels decline rapidly after injection, with minimal systemic accumulation.
Terminal elimination half-life of dinoprostone is 2.5 to 5 minutes; clinical effects persist due to sustained release formulation (e.g., vaginal insert).
Renal: 70-80% as metabolites, 20-30% unchanged; biliary/fecal: <5%
Primarily hepatic metabolism via 15-hydroxyprostaglandin dehydrogenase; metabolites are excreted renally (approximately 60% over 24 hours) and fecally (approximately 40%).
Category C
Category C
Prostaglandin
Prostaglandin